Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Epistem diagnostic test cleared for Hepatitis C trials

The Institut’s approval allows clinical trials of the HCV test to commence
Epistem diagnostic test cleared for Hepatitis C trials
Genedrive detects viral RNA, covers all HCV genotypes and is performed at "point of need" medical centres

-- adds detail, share price --

Epistem Holdings’ (LON:EHP) genedrive diagnostic test has been cleared for clinical trials in Hepatitis C (HCV) by the Institut Pasteur in  Paris.

The qualitative HCV test was developed in collaboration with Inserm, the French National Institute of Health and Medical Research, under a €6m EU supported programme.

The Institut’s approval allows clinical trials of the HCV test to commence in anticipation of regulatory approval and market launch in the EU during 2017, Epistem said.

Ian Gilham, chairman said: "The commencement of clinical trials of our HCV assay is an important step in our ongoing commercialisation of Genedrive, alongside the introduction of our TB test into the Indian market.

“The excellent results seen with HCV serve as a key proof of principle of our ability to develop blood-based tests and allow us to proceed with the development of tests for Hepatitis B and HIV, positioning Genedrive as the point of care platform of choice for the diagnosis of infectious diseases." 

Genedrive detects viral RNA, covers all HCV genotypes and is performed at "point of need" medical centres directly on plasma within 90 minutes.

It is also a qualitative test, not a simple yes or no. This ability to measure the viral load is key for physicians as a new range of anti-viral drugs hits the market, said Gilham.

 An estimated 150 - 200mln people are believed to have chronic HCV viral infection with 350,000 deaths each year from related diseases.

Shares rose 7% to 120p.

 

PhilW.jpg
Why Invest In Genedrive PLC? Read More Here

Register here to be notified of future GDR Company articles
View full GDR profile

Genedrive PLC Timeline

Related Articles

Dimerix [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
Mon
Find out more from Kathy Harrison at Proactive's CEO Spotlight Sessions.
picture of someone with head pain
December 07 2016
Its strategy is to develop cell lines for "off the-shelf" therapies to treat serious conditions
picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use